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Overuse of antibiotics is a major problem in the treatment of bovine mastitis, and
antibiotic treatment is frequently non-curative, thus alternative treatments are necessary.
The primary aim of this study was to evaluate the efficacy of a purified phage
cocktail for treatment of bovine Staphylococcus aureus mastitis in a well-defined
mouse model. Candidate phages were selected based on their in vitro performance
and subsequently processed into an optimally composed phage cocktail. The highest
scoring phages were further tested for efficacy and resistance suppression in broth
and raw milk, with and without supplemental IgG. As these in vitro results displayed
significant decreases in CFU, the cocktail was purified for testing in vivo. Lactating
mice were intramammarily inoculated with S. aureus N305 (ATCC 29740), a clinical
bovine mastitis isolate commonly used for experimental infection of dairy cows. The
phage cocktail was applied via the same route 4 h post-inoculation. Treated mammary
glands were graded for gross pathological appearance and excised for bacterial and
phage load quantification as well as histopathology. Observation of gross macroscopic
and histopathological changes and CFU quantification demonstrated that the phage
cocktail treatment significantly improved mastitis pathology and decreased bacterial
counts. Phage PFU quantification indicated that the tested phage cocktail treatment
was able to maintain high intramammary phage titers without spreading systemically.
The in vivo results complement the in vitro data and support our concept of phage
therapy as an innovative alternative or supplementation therapy to antibiotics for the
treatment of bovine mastitis.
Keywords: antibiotic alternatives, phage therapy, bovine mastitis, S. aureus, mouse model
INTRODUCTION
Bovine mastitis is the most prevalent disease impacting United States dairy cattle (USDA, 2007).
Mastitis is defined as inflammation of the udder, commonly caused by bacterial infection via the
teat canal. Culling rates due to mastitis are typically around 15% of dairy cows in a herd (Jones,
2009). Although several bacterial species can cause mastitis, one of the most problematic pathogens
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is Staphylococcus aureus, a Gram-positive pathogen that infects
between 3 and 15% of dairy cows in a herd (Jones, 2009).
Small-molecule antibiotic therapy is currently used to both
treat and prevent S. aureus mastitis (Bradley and Green, 2001;
Roy and Keefe, 2012; Gomes and Henriques, 2016). Treatment
of clinical mastitis typically occurs during the lactation cycle and
involves selective intramammary (IMM) infusion of antibiotics
into the infected udder quarters. In contrast, during the dry
period (i.e., the period of non-lactation prior to the next
parturition), antibiotics may be administered into all quarters
regardless of their infection status to treat subclinical, undetected
mastitis and prevent the emergence of mastitis both during the
dry period and at the time of parturition. Antibiotic treatment
success rates are highly variable. Despite the antibiotic sensitivity
that most S. aureus mastitis isolates display in vitro (Erskine et al.,
2006; Lindeman et al., 2013), they are more difficult to eliminate
in vivo with reported clinical mastitis cure rates as low as 4%
(Barkema et al., 2006). Although milk is rigorously tested for
antibiotic residues, consumers have nevertheless become more
concerned about antibiotics in the food supply (Lusk et al.,
2006). The perception of overuse of antibiotics in human and
veterinary medicine has also caused concern, motivating the
United States government in 2015 to release the National Action
Plan for Combating Antibiotic-Resistant Bacteria (House, 2015).
Thus, there is an unmet need to discover and develop alternative
treatments for mastitis that do not rely on small-molecule
antibiotics. Phage-based treatments offer promising potential as
a therapeutic and/or preventative alternative to antibiotics due to
their host specificity, thereby preserving the healthy microbiome,
and their potential for avoiding antibiotic residues in milk.
A wide variety of publications in the agricultural realm support
their use, (example reviews Johnson et al., 2008; Atterbury, 2009).
Currently, a withholding period is imposed after completing a
course of antibiotic therapy in dairy cattle to allow the animal
to eliminate the antibiotic from its system prior to returning to
production for human consumption. The length of this period
is determined by route of administration and pharmacokinetic
properties of the specific drug, and residue studies are performed
prior to product approval to determine when milk and meat from
the cows is acceptable for consumption. During the withholding
period, the antibiotic-contaminated milk must be discarded and
the animal cannot be culled for the purpose of meat consumption.
Milk discarded comprises one of the major negative economic
impacts of mastitis (Halasa et al., 2007). If phage therapy were to
be granted a zero withholding period based on a positive human
food safety profile, the presence of any residual phage in meat
or milk would be of no concern, it would benefit producers by
reducing losses due to discarded milk and if appropriate, send
cattle to slaughter sooner.
The primary aim of this pilot study was to evaluate for the
first time the efficacy of a S. aureus phage cocktail containing an
equal mixture of two selected top candidates using a validated
murine model for bovine mastitis. This preclinical model has
been established as an effective screening tool for potential
bovine mastitis therapies (Brouillette et al., 2004; Brouillette and
Malouin, 2005; Notebaert and Meyer, 2006). The phage cocktail
efficacy was compared to the efficacy of a commercial antibiotic
(used as positive control). Safety served as a secondary aim
and was evaluated in an uninfected phage-only treated group
of mice. The obtained results indicate a significant decrease in
bacterial counts, decreased gross pathological signs and a lack of
pathological response to this in vitro optimized phage cocktail,
providing preclinical evidence for the success of phage therapy
for treatment of bovine mastitis.
MATERIALS AND METHODS
Phage Cocktail Formulation
Each phage within a panel of 12 potential cocktail candidates
was tested using quantitative measures of infection including
efficacy and kinetics of killing, amplifiability, time to resistance
emergence, genomic relatedness, and phage–phage interaction
(data not shown). Phages were characterized singly and as
cocktails to determine the most optimal cocktail composition.
The two highest-scoring phages across these categories were
selected for the therapeutic cocktail used in this study. The first
of the two phages included in the final cocktail was derived
from an in-house directed evolution protocol from parent
Myovirus phage ATCC 23361. The second phage, BP39, was
generously provided by PhageLux (GenBank accession number
NC_031046).
In Vitro Testing
Staphylococcus aureus N305 was selected for use in this study.
This strain is a bovine mastitis isolate that has been widely
used for experimental infection of dairy cows and mice (Breyne
et al., 2014; Peton et al., 2014). The phage cocktail was tested
in tryptic soy broth (TSB, Becton Dickinson) and raw milk
(Organic Pastures) with the addition of bovine IgG (Equitech-
Bio) as a potential inhibitor of phage activity as previously
reported (O’Flaherty et al., 2005a; Gill et al., 2006b; Tanji et al.,
2015). The reported IgG concentration in milk varies between
studies, however, for healthy milk it has been reported to be
0.45–1.34 mg/mL and for mastitic milk, 3–15 mg/ml (Tomassetti
et al., 2013). In-house testing of a variety of store-purchased, raw,
and mastitic milk samples (Bovine IgG ELISA Kit from Alpha
Diagnostics, data not shown) revealed a broad range as well. Thus
5 and 20 mg/mL were chosen as a low and high representative
concentration.
Culture conditions were designed to closely mimic those
present in the mouse model. Bacterial cultures used in the
experiment were prepared from exponential phase cultures
[Optical density at 600 nm (OD600 nm) = 0.3−0.6], and diluted
to 2.5 × 103 CFU/mL in a final volume of 200 µl of TSB or
milk. These were shaken at 250 rpm horizontally in Eppendorf
tubes at 37◦C with supplemental IgG at 5 and 20 mg/mL for
4 h prior to the addition of phage. Prior to the experiment
raw milk was tested on agar plates selective for S. aureus (CSA,
CHROMagar) to verify that contaminating S. aureus were not
present. IgG solutions were prepared by suspending lyophilized
IgG in reagent grade water to a final concentration of 100 mg/mL,
then filtering it through a 0.2 µm PES filter into a sterile Falcon
tube. Both S. aureus phages from the selected phage cocktail were
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combined by diluting in sterile phosphate buffer saline (PBS) to
5 × 109 PFU/mL per phage (1 × 1010 PFU/mL total). After 4 h
of pre-treatment incubation, 200 µl of this phage cocktail was
added to each Eppendorf tube to a final volume of a 400 µl
and returned to 37◦C shaking as before. After 3 and 18 h of
incubation bacterial growth was assessed by taking 15 µl from
each sample and performing serial dilutions in PBS using 96-
well microplates. Next, 3 µl of each dilution was spotted on a
CSA plate and incubated at 37◦C overnight. On the next day
pink/mauve S. aureus colonies were counted and CFU/mL was
calculated for each sample.
Phage Cocktail Amplification and
Purification
Phage stocks were amplified on S. aureus N305 growing in
TSB (Difco TSB powder dissolved in endotoxin-free water, used
throughout to minimize endotoxin input) in Fernbach flasks
using amplification and lysing conditions similar to (Bryan et al.,
2016). Briefly, 1 L cultures were grown to OD600 nm ∼ 0.2
(∼4 × 107 CFU) and were infected at a multiplicity of infection
(MOI) of 0.1 and incubated at 37◦C for 4 h with shaking at
250 rpm before lysing with 2 mL of CHCl3. The resulting phage
lysates were incubated overnight statically at room temperature
in the dark. The following day, cultures were separated from any
remaining chloroform and centrifuged for 20 min at 5353 × g to
pellet bacterial debris, after which the supernatant was sterilized
by membrane filtration through a 0.2 µm polyethersulfone
(PES) filter. The resulting solution was concentrated using
tangential flow filtration and the retentate product was then again
sterilized by filtration through a 0.2 µm PES filter. Concentrated
stocks were purified using anion exchange chromatography
(Adriaenssens et al., 2012) with separate strong anion exchanger
columns for each phage with a subset of the elutions containing
the highest phage titers being buffer exchanged either using
a size exclusion column or tangential flow filtration system
into Ringer’s solution (116 mM NaCl, 2.9 mM KCl, 1.8 mM
CaCl2∗H2O, 5 mM HEPES Buffer). Buffers used for all three
systems were filtered-sterilized and prepared using endotoxin-
free water.
Prior to final cocktail formulation and treatment, the purity
of each phage solution was assayed by measuring the following
parameters: phage titer was measured using a standard double
agar plating method; bacterial DNA levels were quantified
by qPCR-amplifying 16S rRNA (the calculated concentration
of bacterial DNA took into account the average of five 16S
copies and 2,782,562 base pairs present per one genome and
plasmid of N305); endotoxin levels were measured using the
Lonza Chromogenic Endpoint LAL assay; and finally, S. aureus
host cell proteins (HCP). HCP was measured at various
purification steps using several methods to demonstrate the
amount of protein reduction. While these methods were not
strictly quantitative, the large fold-reduction of values was
sufficient to proceed with the in vivo studies. Briefly, an area
under the curve analysis of the real time ultraviolet readings
(280 nm) from anion exchange chromatograms showed a
+85% reduction/separation of proteins from fractions used
for the study (data not shown). Second, a gradient sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
of various stages of purification showed several bands present
in the mock lysate that were absent in each subsequent step
of the purification process. A commercial S. aureus HCP
enzyme-linked immunosorbent assay (ELISA) quantitation kit
was tested (Cygnus F320) but control experiments indicated
it did not detect N305. The sterility of individual post-
buffer exchanged phage stocks and the final formulation was
verified by streaking 20 µL aliquots onto TSA plates and
incubating at 37◦C for 3 days; plates were checked for
colonies daily. Aliquots for injection were prepared under
laminar flow conditions and filtered with a 0.2 µm PES
membrane.
Infectious Inoculum Preparation
A −80◦C frozen S. aureus N305 stock was thawed and grown
for 6 h in brain heart infusion (BHI) medium (Oxoid) at 37◦C
and subcultured in the same conditions overnight. The inoculum
was centrifuged for 15 min at 3220 × g and washed twice
with 10 ml PBS. The number of bacteria was subsequently
measured in the inoculum through measurement of OD600nm on
a spectrophotometer. Based on these OD results the inoculum
was diluted in PBS to the desired number of bacteria. The exact
number of CFU of the inoculum was confirmed by plate counts
on tryptone soya agar (TSA) plates (Oxoid). An average inoculum
dose of 3.45× 102 CFU/gland was used. All test compounds were
injected into the glands at 4 h post-inoculation in a volume of
100 µL.
Mouse Mastitis Model of Infection
Animal experiments were conducted according to Good
Scientific Practice-principles and approved by the Ethical
Committee of the Faculty of Veterinary Medicine, Ghent
University (approval number EC 2015/127). CD-1 mouse dams
(Envigo, Horst, Netherlands) were used 10–14 days after birth
of their offspring. The female lactating mice typically weighed
40 g to 50 g at time of use. The pups were removed
1–2 h prior to bacterial inoculation of the mammary glands.
A mixture of oxygen and isoflurane (2–3%) was used for
inhalational anesthesia of the mice and a bolus of PBS-
diluted Vetergesic (i.e., buprenorphine 10 µg/kg, Val d’Hony
Verdifarm NV, Belgium) was administered intraperitoneally
(i.p.) as analgesic prior to any surgical intervention. A syringe
with 32-gauge blunted needle was used to inoculate both
L4 (on the left) and R4 (on the right) of the fourth
abdominal mammary gland pair with 3.45 × 102 CFU/gland
of S. aureus (t = 0). Each orifice was exposed by a small
cut at the near end of the teat and 100 µL of inoculum
was injected slowly through the teat canal. After 4 h, the
phage cocktail-treated groups received an intramammary dose of
3 × 107 PFU (120 µl). S. aureus-infected mice that were treated
after 4 h through intramammary injection of 100 µg/gland
cefalonium (i.e., a first generation cephalosporin antibiotic used
in the dairy industry to treat typically Gram-positive mastitis
infections) were also included in the study as a positive control
group.
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Clinical and Gross Parameters:
Quantifying Bacteria and Phage in
Samples from Mammary Glands and
Blood
At 24 h post-inoculation (p.i.) with S. aureus, mice were sedated
i.p. with a ketamine and xylazine mixture prior to sacrifice by
cervical dislocation and sampling the injected glands (two per
mouse) and blood. Upon sacrifice, the L4 and R4 mammary
glands were harvested to quantify both bacteria and phage.
Bacterial CFU counts and phage (PFU) counts were obtained
after plating serial logarithmic dilutions of mammary gland
homogenates, counting colonies or plaques, and transforming
counts into base 10 logarithm (log10) values. The limits of
detection (LOD) were 100 CFU/g of gland and 100 PFU/g
of gland, respectively. In addition, blood samples were taken
by cardiac puncture from all mice of the uninfected safety
control group (only treated with phage cocktail), and plasma
was prepared and tested for PFU. Representative images of
mammary gland pairs were taken for each group and scored
based on clinical and gross parameters by expert veterinarians
using a scoring scale from 1 (mild inflammation) to 5 (severe
inflammation).
Histopathological Evaluation of Necrosis
and Immune Cell Infiltration
Isolated mammary gland tissue was fixed for 24 h in buffered
paraformaldehyde. Representative sections of tissue samples were
trimmed and placed in tissue processing cassettes and routinely
processed in graded alcohol, cleared in xylene and embedded in
paraffin. Paraffin-embedded tissues were sent to Vdx Veterinary
Diagnostics (Davis, CA, United States) for histological slide
preparation, evaluation and histological scoring. Paraffin blocks
for two animals per group were sectioned on a microtome at
4–6 µm, mounted on glass slides and stained with hematoxylin
and eosin (H&E) for routine light microscopic evaluation. The
pathologist remained blinded to treatment groups during the
histopathological examination.
Each sample was evaluated for presence of necrosis,
polymorphonuclear neutrophilic granulocyte inflammation (i.e.,
neutrophilic inflammation), lymphocytic inflammation and
bacteria. Each feature was graded semi-quantitatively in ten
different high power fields at 200×magnification and an average
score for each category was calculated. The semi-quantitative
scoring was performed using the following criteria: 0 = Absent,
the histologic feature (necrosis, neutrophils, lymphocytes, or
bacteria) was not observed in the examined 200× field;
1 = Minimal, the histologic feature (necrosis, neutrophils,
lymphocytes, or bacteria) was present in scant or very small
amount in the examined 200× field; 2 = Mild, the histologic
feature (necrosis, neutrophils, lymphocytes, or bacteria) was
consistently present in low numbers through the examined
200× field and normal tissue architecture was maintained;
3 = Moderate, the histologic feature (necrosis, neutrophils,
lymphocytes, or bacteria) was a prominent and distinctive feature
in the examined area (i.e., the majority of glands or tissue
in the area exhibited some necrosis, presence of neutrophils,
or lymphocytes); 4 = Severe, the histologic feature (necrosis,
neutrophils, or lymphocytes) was an overwhelming feature of
the examined 200× field, in general all glands in the area were
affected and normal architecture of the gland was obscured.
Quantitative analysis of bacteria is not possible in histological
sections.
Statistical Analysis
Statistical analysis of the in vivo data was performed in SPSS and
GraphPad Prism, in vitro analysis in GraphPad Prism. Because
the residuals were not normally distributed, significance was
determined with a non-parametric Kruskal–Wallis test followed
by Dunns post hoc testing for the in vivo data, and Mann–
Whitney for the in vitro and histological data.
RESULTS
In Vitro Testing of Phage Cocktail
Efficacy
The efficacy of a cocktail comprising equal abundances of
the two phages was examined in vitro using S. aureus N305.
The phage cocktail was tested both in TSB and in raw milk
with the addition of IgG as a potential inhibitor of phage
activity after 4 h of bacterial growth (Figure 1). Irrespective of
the added IgG concentration, the phage cocktail significantly
reduced CFU in all treatment cultures (p < 0.05) to below
the LOD (1 × 103 CFU/mL), demonstrating 3–6 orders of
magnitude of killing in broth culture, and 2–4 orders of
magnitude in milk. The addition of IgG had no significant
impact on CFU in milk or at 4 h in broth (Figures 1A,C,D).
However, at 18 h in broth (Figure 1B) a significant decrease
was observed (Mann–Whitney, 0 vs. 5 mg/mL – P < 0.05;
0 vs. 20 mg/mL – P < 0.05). IgG addition demonstrated no
detected impact on phage activity regardless of time or Raw milk
in some instances demonstrated background contamination,
which was not observed upon phage treatment. Based on
these positive results, in vivo testing of the phage cocktail was
pursued.
Phage Cocktail Purification
After the phage treatment solution was purified and titered, it
was assessed for the presence of bacterial DNA, endotoxin, and
S. aureus host cell proteins. Each of these parameters were found
to be within internally defined acceptable limits, which were
based on ascertainable regulatory purity guidelines and published
industry standards when available. These values are, per dose:
3 × 107 total PFU, 0.42 EU of endotoxin, and 1.025 ng of host
DNA. See “Materials and Methods” section for details of host cell
protein testing.
In Vivo Phage Treatment in a Mouse
Model of Bovine Staphylococcal Mastitis
Colony Forming Units
At 24 h p.i. with S. aureus, mammary glands of mice that received
PBS (sham, negative control group) had a median bacterial load
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FIGURE 1 | In vitro bacteriophage cocktail activity in broth and milk. Bacterial cultures in media (A,B) and raw milk (C,D) were grown for 4 h, then treated with
phage. 3 (A–C) and 18 (B–D) hours later cultures were plated for CFU. Each circle on the graph corresponds to the CFU/mL value of an individual replicate. Lines
represent the median value for each group. Statistically significant differences were observed in all phage-treated cultures, at both time points and regardless of IgG
concentration (P < 0.05, Mann–Whitney).
FIGURE 2 | Mammary gland CFU post phage treatment. Twenty-four hours
after infection mammary glands were excised, homogenized, and plated in
order to count bacterial CFU. Conditions are (1) PBS treatment (negative
control group), (2) cefalonium treatment (positive control group), or (3)
bacteriophage cocktail treatment (phage treatment group). Each circle on the
graph corresponds to the log10 CFU/g value of an individual gland. The bar
represents the median value for each group. The significant differences
between the median values are indicated with (∗P < 0.05, ∗∗∗P < 0.001,
Kruskal–Wallis) and the dotted line indicates the detection limit (DL).
of 8.70 log10 CFU/g of gland which represents an increase of
6.16 log10 CFU/g of gland compared to the original inoculum
(Figure 2). In contrast, mammary glands from mice that received
cefalonium (positive control group) had bacterial loads at or
below the LOD (Figure 2). Mammary glands from mice that
received the phage cocktail (phage treatment group) had median
bacterial loads of 4.43 log10 CFU/g of gland, significantly lower
than the negative control group (p < 0.001, Figure 2).
Gross Pathology
Mammary glands were graded for gross pathological appearance
(Figure 3) which demonstrated significant differences between
the negative control group (median score = 3.3), the positive
control group (median score = 1.0) and the phage treatment
group (median score = 1.1). Mammary glands of the non-
infected phage-treated mice had a median score of 1.5 (not
significantly different from any other group, p > 0.05).
Representative post-mortem pictures of mammary glands are
shown in Figure 4. Mild or lack of inflammation was
characterized by the presence of milk in the mammary glands,
while redness of the glands indicated a severe local inflammatory
reaction accompanied with a slimy exudate, indicative of a high
bacterial burden.
Descriptive Histopathology
Representative images after histopathological examination are
shown in Figure 5. Descriptions of each group follow:
Infected plus phosphate-buffered saline (sham) treatment
Representative sections of mammary tissue from animals
in this group were characterized predominately by patchy
to coalescing intraglandular neutrophilic infiltration with
frequent large colonies of coccoid bacteria. The neutrophilic
inflammation was often degenerate and intermixed with
fragmented nuclear debris. The lining epithelial cells were
typically attenuated, discontinuous or otherwise distorted with
Frontiers in Microbiology | www.frontiersin.org 5 November 2017 | Volume 8 | Article 2348
fmicb-08-02348 November 25, 2017 Time: 16:27 # 6
Breyne et al. Phage Cocktail for Treating Mastitis
FIGURE 3 | Clinical scoring of mammary glands. Mammary glands were
scored from 1 (mild inflammation) to 5 (severe inflammation) by seven
independent veterinarians. Each circle on the graph represents one gland, and
the bar represents the median value for each group. Conditions are (1) PBS
treatment (negative control group), (2) cefalonium treatment (positive control
group), (3) bacteriophage cocktail treatment (phage treatment group), and (4)
uninfected mice infused with the phage cocktail (safety control group). The
significant differences between the median values are indicated with
(∗∗P < 0.01, ∗∗∗P < 0.001, Kruskal–Wallis).
fading nuclei (karyolysis). Active sloughing of the degenerating
epithelial cells into the glandular lumen was frequent. Rounded,
hypereosinophilic epithelial cells with pyknotic nuclei were seen
to a lesser extent. The glands also contained a variable amount of
proteinaceous and lipid-rich secretion.
Infected plus phage treatment
Representative sections of mammary tissue from this group
were characterized by glands that were consistently lined by
robust, cuboidal epithelial cells that exhibited a variable degree
of clear cytoplasmic vacuolation. The glandular lumina mostly
contained flocculent to slightly globular proteinaceous secretion
with modest lipid content. Sloughed, intraglandular epithelial
cells that appeared rounded and hypereosinophilic with pyknotic
nuclei (interpreted as necrotic or apoptotic) were present
in minimal to mild numbers. Patchy, minimal neutrophilic
inflammation was recognized only in one gland.
Infected plus cefalonium treatment
Representative sections of mammary tissue from this group were
lined by epithelial cells that were variably mildly attenuated
to often robust with abundant cytoplasm with lipid vacuoles.
The luminal contents consisted mostly of flocculent to lipid
laden, proteinaceous secretion and included a variable, minimal
to moderate, degree of necrotic (or apoptotic) epithelial cells
characterized by rounded, hypereosinophilic cytoplasm and
pyknotic nuclei. Sparse neutrophilic inflammation was rarely
identified. Minimal interstitial lymphocytic inflammation was
also identified.
Uninfected plus phage treatment
Representative sections of mammary tissue from this group
generally contained mild to moderate numbers of sloughed
necrotic (or apoptotic) epithelial cells characterized by rounded
borders, hypereosinophilic cytoplasm and pyknotic nuclei.
The glandular epithelium ranged from attenuated to robust
with cuboidal shape with variable degree of cytoplasmic lipid
vacuolation. The luminal contents also included flocculent
proteinaceous secretion without obvious high lipid content.
Only one gland exhibited minimal neutrophilic inflammation.
Minimal to mild numbers of interstitial lymphocytes were also
identified.
Histopathology scoring
Sectioned and stained tissues were blindly scored on a semi-
quantitative scale (Figure 6). Infected PBS-treated mammary
glands (group 1) showed moderate necrosis (black bars), had
the highest neutrophilic inflammation (white bars) and highest
bacteria scores (diagonal bars). Infected cefalonium treated
mammary glands (group 2) did not display a significant decrease
in necrosis or lymphocytes compared to the infected PBS-
treated glands, but were lower in neutrophil numbers as well
as bacteria. Infected phage treated mammary glands (group 3)
showed the lowest scores for necrosis, and unlike the infected
cefalonium treated glands these were significantly lower than the
infected PBS- treated glands. They also had significantly lower
neutrophilic scores, mild to moderate lymphocytic inflammation
(horizontal bars) and did not have observable bacteria. As
expected, the uninfected phage treated mammary glands (group
4) had low neutrophilic, lymphocytic and bacterial scores, similar
to those observed for both the cefalonium and the phage treated
infected groups, however, they had the highest necrosis score. All
groups had minimal and similar lymphocytic scores.
Clinical Observations
Clinical behavior was also affected in the infected PBS-treated
mice. These mice were less motile and were grouped together
in the cage, in marked difference to all other treatment groups,
which the mice were very alert and active. As motility can be
depressed by hypothermia, core body temperature of the mice
was measured before sacrifice. Infected PBS-treated mice had the
lowest average core body temperature (35◦C), while those from
the phage treated infected group had the highest average core
body temperature (36.1◦C), however, this latter observation did
not reach significance (P> 0.05). This indicates that all mice were
sacrificed before reaching their humane endpoints.
Plaque Forming Units
At 24 h p.i. no phages were detected in the mammary glands
of either the PBS treated or the cefalonium treated infected
groups (Figure 7). In phage treated mice mammary glands either
infected or uninfected had similar PFU. The PFU of all phage-
treated groups indicate a reduction of the original bacterial
inoculum, with a median value (log10 PFU/g of gland) of infected
plus phage treatment of 6.69, and a median value of uninfected
plus cocktail of 6.08, vs. the inoculum value of 7.6. (Figure 7).
Interestingly, the infected plus phage group PFU counts were
slightly higher relative to those of the uninfected plus phage
group (i.e., 6.69 vs. 6.08). Although this difference was not
statistically significant, it suggests that the phages productively
infected their S. aureus host and were likely amplified. Regarding
systemic spread, LOD of 2.45 log10 PFU/g gland.
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FIGURE 4 | Gross pathology of mammary glands. Representative photographs from dissected mice are shown. Conditions are (1) PBS treatment (negative control
group), (2) cefalonium treatment (positive control group), (3) bacteriophage cocktail treatment (phage treatment group), and (4) uninfected mice infused with the
phage cocktail (safety control group). Macroscopic differences resulting from the different treatments of the infected mammary glands are clearly visible (e.g.,
prominent redness and inflammation in 1), and reflected in the scores in Figure 3.
DISCUSSION
The current study investigated the potential of phage therapy for
the treatment of bovine staphylococcal mastitis, by combining
complementary in vitro and in vivo strategies. Following
the in vitro characterization and selection of a promising
bacteriophage cocktail, a preclinical mouse model for bovine
mastitis was used to study the in vivo effects of this candidate
therapy against S. aureus.
It was first demonstrated in vitro that S. aureus was reduced
to below the detection limit by the phage cocktail both in
media as well as in raw milk, regardless of IgG concentration.
This latter is a key observation as it differs from the results
of several previous studies (Das and Marshall, 1967; O’Flaherty
et al., 2005a; Gill et al., 2006b; Tanji et al., 2015) which reported
a either a lack of or a significant reduction of phage activity
in raw milk or its components. These authors attributed this
observation to either whey protein binding of the bacterial cells
or bacterial aggregation, purportedly driven by IgG lowering the
adsorption rate of phage (Tanji et al., 2015). Although bacterial
aggregation was not directly examined as a part of this study,
CFU counts suggest that it did not generally occur, as increases
in IgG concentration would lead to fewer CFU if aggregation
took place. This was true, with the exception of TSB at 18 h.
The lack of aggregation in our study is in marked contrast to the
three previously cited papers and may be attributable to strain-
level variability in aggregation potential. Biofilm and aggregate
formation are complex and multifactorial processes in S. aureus,
and variability between strains has been observed by us (data not
shown) and others (Haaber et al., 2012; Thammavongsa et al.,
2015). In the Tanji report, a different bovine mastitis isolate was
used, SA003 (NBRC 110649) (Tanji et al., 2015), and O’Flaherty
used the S. aureus strains DPC5246 and DPC5645 from the Dairy
Products Research Centre culture collection (O’Flaherty et al.,
2005a). Thus it is possible that the strain used in this study, N305,
does not aggregate to the same degree as these other strains.
However, N305 was also used in a study in which whey proteins
were demonstrated to inhibit phage activity (Gill et al., 2006b).
Although the specific cause or causes of these different results is
unknown, it may at least partly be explained by factors such as the
use of different phages, the variability inherent in raw milk, and
differences in experimental design.
The preceding in vitro bacteriophage characterization was
performed to successfully select therapeutic phage candidates,
prompting further investigation to correlate in vitro phage
performance with in vivo efficacy against bovine S. aureus.
Quantitative bacterial loads, histological evaluation, and
qualitative clinical and gross macroscopic changes all strongly
indicated that treatment with the phage cocktail significantly
decreased the intramammary bacterial loads and inflammation
caused by the bovine mastitis isolate S. aureus N305. Moreover,
the quantitative PFU counts strongly indicated that the phage
treatment was able to maintain high local phage titers in
the murine mammary gland (Figure 7) without spreading
systemically.
Of particular interest is the improvement in clinical outcome
in phage-treated mice, as measured by gross pathology and
clinical ante-mortem observation, despite the failure of phage
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FIGURE 5 | Histopathology. Representative H&E stained tissue sections from each group are shown. (1) Infected plus PBS treatment. Mouse mammary gland.
Moderate to severe neutrophilic inflammation and bacterial colonization (dark purple) of mammary glands. The lining epithelium exhibits various stages of
degeneration, necrosis and sloughing. (2) Infected plus cefalonium treatment. Healthy epithelial cells lining normal glandular tissue that contains a modest amount of
flocculent proteinaceous secretion and rare sloughed necrotic or apoptotic cells. (3) Infected plus phage treatment. This image demonstrates healthy glandular
epithelial cells characterized by robust cuboidal shape and a variable degree of clear cytoplasmic vacuolation (lipid). These cells are lining normal glandular tissue that
contains a modest amount of flocculent proteinaceous secretion. (4) Uninfected plus phage. This gland is characterized by mild to moderate numbers of sloughed
necrotic or apoptotic cells. The intact lining epithelium is otherwise normal.
to achieve microbiological cure as observed with cefalonium
treatment (Figure 2). The gross appearance of the tissues,
along with the behavior and appearance of the mice, closely
matched the cefalonium treated group. Phage are known to
live in symbiosis with bacteria and follow a predator/prey
PK/PD (pharmacokinetic/pharmacodynamic) model (Lenski and
Levin, 1985; Drulis-Kawa et al., 2012), meaning that depending
on the conditions phage alone may not completely eliminate
microbial populations in the way small molecule antibiotics
do. The clinical benefit may lay in the ability to reduce
pathogen burden to the point that the host immune system
can resolve remaining infection, a benefit observed in phage
trials that demonstrate microbiological cure (Kutter et al.,
2010; Abedon et al., 2011). Had the our experiments been
carried out beyond 24 h it is possible that further reduction
in CFU would have similarly been observed, due to the
immune response as well as due to continued activity of phage
infection. However, additional time can increase the risk of the
development of bacterial resistance. Although microbiological
cure is ultimately necessary in a S. aureus mastitis treatment,
early clinical improvement may still allow a more rapid return
to production.
Last but not least, phage treatment of uninfected glands
appeared to be safe and well-tolerated. Treatment did not induce
significant inflammation by gross pathological observation, and
histological evaluation did not reveal significant differences
between either neutrophilic or lymphocytic inflammation. Phage
treatment is also considered as generally safe for humans, which
has been confirmed numerous times in patients from the Phage
Therapy Unit at Hirszfeld Institute (Miedzybrodzki et al., 2009).
In humans, phage therapy has been recently reported as being
both safe and successful (Schooley et al., 2017) and was reviewed
by Kutter et al. (2010) and Schooley et al. (2017). Moreover, it has
been suggested that the application of phage preparations may
probably influence and diminish the inflammatory reaction that
accompanies bacterial infection in humans as well (Górski et al.,
2016). However, the necrosis score for this group was the highest
of the four groups. This appears paradoxical, as the infected
and phage treated group encouragingly had a significantly
lower necrosis score. Although the necrosis scores were similar
between infected PBS-treated and uninfected phage treated, the
histopathology of the two lesions were qualitatively different.
Moreover, the mechanism underlying this observed necrosis is
unclear. A recent publication on the histopathology of S. aureus
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FIGURE 6 | Histological scoring. Tissue sections from excised glands from
two mice were processed for histological scoring and read by a veterinary
pathologist. Scores (y-axis) represent the average of 10 semi-quantitative
evaluations for each gland using the following criteria (see Materials and
Methods for detailed explanation): 0 = Absent, 1 = Minimal, 2 = Mild,
3 = Moderate, 4 = Severe. Groups consist of: black bars = Necrosis, white
bars = PMN, horizontal striped bars = Lymphocytes, and diagonal striped
bars = Bacteria. Conditions are (1) PBS treatment (negative control group), (2)
cefalonium treatment (positive control group), or (3) bacteriophage cocktail
treatment (phage treatment group), and (4) uninfected mice infused with the
phage cocktail (safety control group). Statistically significant differences were
observed between PBS treatment (1) and cefalonium (2) or PBS treatment (1)
and phage treatment (3) where indicated (∗P < 0.05, ∗∗∗∗P < 0001,
Mann–Whitney). Error bars represent standard deviation.
FIGURE 7 | Mammary gland PFU post phage treatment. After
Staphylococcus aureus infection and treatment mammary glands were
excised, homogenized, and plated on bacterial lawns in soft agar for PFU
determination. Conditions are (1) PBS treatment (negative control group), (2)
cefalonium treatment (positive control group), or (3) bacteriophage cocktail
treatment (phage treatment group), and (4) uninfected mice infused with the
bacteriophage cocktail (safety control group). Each circle on the graph
corresponds to the log10 PFU/g value of an individual gland. The bar
represents the median value for each group. The significant differences
between the median values are indicated with ∗P < 0.05, ∗∗∗P < 0.001,
Kruskal–Wallis). Dotted lines represent the limit of detection (LOD) and the
phage inoculum dose (inoculum).
mastitis states that necrosis can be induced by neutrophil influx
migration (Chinchali and Kaliwal, 2014), yet at the 24-h time
point this phenomenon was not observed histopathologically.
The most likely explanation relates to the involution that
takes place upon weaning of the pups prior to inoculation
in the mouse mammary gland infection model. Involution
safeguards the host from extensive inflammation in the post-
lactation period (Watson, 2006). Normal involution typically
causes very rapid and massive cell death by apoptosis, hence
the rounded, hypereosinophilic cells with pyknotic nuclei are
more likely cells undergoing this natural apoptosis, rather
than necrosis. The histomorphology of cellular necrosis and
apoptosis may not always be distinctively different. Further, an
accurate interpretation of histological necrosis often requires
a broader context than is provided in a blinded evaluation.
In the context of this study, high “necrosis” scores without
associated gross confirmation or accompanying histological
inflammation can more likely be attributed to controlled or
programmed cellular death (i.e., apoptosis) rather than cellular
death due to disease, injury or ischemia (i.e., necrosis). Because
these intracellular Gram-positive bacteria are typically the
most difficult to eradicate from the (bovine) mammary gland
with standard antibiotic treatment, this intriguing phenomenon
warrants further investigation. Finally, the same authors state
that “tissue damage can initially be caused by bacteria and
their products.” Purification to remove contaminants and quality
testing was performed on the phage treatment solution, however,
it is conceivable that a low local contaminant level, such as
endotoxin or a S. aureus toxin, sufficient to induce necrosis
remained.
Overall, the phage-only inoculated group demonstrated no
gross clinical symptoms or observable macro- or microscopic
deleterious findings, consistent with data from two previous
studies that treated 6–8 weeks old mice with either phage K
(Gill et al., 2006a) or phage φMR11 (Matsuzaki et al., 2003)
by intraperitoneal injection, although both these purification
methods differed from the one used herein. Of interest, the phage
K study, in which dairy cattle received intramammary infusions
of phage K, reported an increase in somatic cell count (Gill et al.,
2006a). This is interesting in light of the current findings, as it is
feasible that the increase in cell count was due to apoptotic cells
rather than an inflammatory response as we postulate herein. It
is also feasible that it could be caused by an immune response to
contaminants in the treatment, or to the phages themselves. In
contrast, another similar bovine study in which two phages were
intramammarily infused reported no such response (O’Flaherty
et al., 2005b).
CONCLUSION
The combined in vitro and in vivo results of the current
study indicate that phage therapy is a promising alternative to
antibiotics for the treatment of bovine staphylococcal mastitis.
Although this innovative strategy was independently proposed
by three other groups, those studies date from more than a
decade ago (Matsuzaki et al., 2003; O’Flaherty et al., 2005b; Gill
et al., 2006a), and the bacteriophages were hampered by bovine
whey proteins inhibiting their interaction with S. aureus. The
latter was not an issue with our novel bacteriophage cocktail.
Besides a direct antibacterial effect, a synergistic effect with the
classical antibiotics can also be envisaged, potentially allowing
a lower dose and/or shorter treatment with these drugs. Future
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research will focus on validating this pilot study in an inoculum
dose-titration study to determine the optimal phage dose for
S. aureus treatment and clinical improvement, and provide the
basis for further translation of our proof-of-concept in dairy
cattle. Future directions may include iterating this process to
establish a relationship between individual phage characteristics
and in vivo performance to refine the phage scoring metrics so as
to enable predictive, high-throughput selection of good candidate
phages for future therapeutic cocktails.
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